ARIAD Pharmaceuticals Newswire

ARIAD Pharmaceuticals Newswire

Comprehensive Real-Time News Feed for ARIAD Pharmaceuticals.

Results 1 - 20 of 494 in ARIAD Pharmaceuticals

  1. Press release distribution, EDGAR filing, XBRL, regulatory filingsRead the original story w/Photo

    Yesterday | Business Wire

    In addition, Pioneer Investments is announcing special one-time tax... )--ARIAD Pharmaceuticals, Inc. , a rare cancer-focused innovative biotechnology company, today announced a conference call and webcast to discuss the cl... )--Ryman Hospitality Properties, Inc. today announced that its Board of Directors declared a cash dividend of $0.75 per share of common stock payable on ... )--B&G Foods, Inc. announced that effective today it has acquired Victoria Fine Foods Holding Company and Victoria Fine Foods, LLC from Huron Capital... )--The combined consumer and enterprise worldwide wireless local area network market segments increased 1.8% year over year with revenues of $2.47 billion in... )--Fitch Ratings has downgraded the following Port Huron, Michigan ratings to 'A' from 'A+': -- $1.73 million general obligation limited tax refunding bonds series 2006... ExxonMobil Announces Tom ... (more)

    Comment?

  2. Press release distribution, EDGAR filing, XBRL, regulatory filingsRead the original story w/Photo

    7 hrs ago | Business Wire

    In addition, Pioneer Investments is announcing special one-time tax... )--ARIAD Pharmaceuticals, Inc. , a rare cancer-focused innovative biotechnology company, today announced a conference call and webcast to discuss the cl... )--Ryman Hospitality Properties, Inc. today announced that its Board of Directors declared a cash dividend of $0.75 per share of common stock payable on ... )--B&G Foods, Inc. announced that effective today it has acquired Victoria Fine Foods Holding Company and Victoria Fine Foods, LLC from Huron Capital... )--The combined consumer and enterprise worldwide wireless local area network market segments increased 1.8% year over year with revenues of $2.47 billion in... )--Fitch Ratings has downgraded the following Port Huron, Michigan ratings to 'A' from 'A+': -- $1.73 million general obligation limited tax refunding bonds series 2006... ExxonMobil Announces Tom ... (more)

    Comment?

  3. Ariad Pharmaceuticals' (ARIA) Positive Rating Reiterated at Leerink SwannRead the original story w/Photo

    8 hrs ago | IntersportsWire

    Several other equities research analysts have also recently weighed in on ARIA. Zacks Investment Research upgraded shares of Ariad Pharmaceuticals from a hold rating to a strong-buy rating and set a $16.00 price objective for the company in a research report on Wednesday, September 28th.

    Comment?

  4. Why Ariad Pharmaceuticals Soared 47% in NovemberRead the original story w/Photo

    11 hrs ago | Fox News

    Only a month after news of significant price increases on its only commercial drug caused its shares to drop, Donald Trump's victory caused Ariad Pharmaceuticals ' Iclusig treats chronicmyeloid leukemia and Philadelphia chromosome positive acute lymphoblastic leukemia , two rare blood and bone marrow diseases. The drug is an important treatment option for these patients.

    Comment?

  5. ARIAD to Host Webcast and Conference Call on Brigatinib Data...Read the original story

    12 hrs ago | Customer Interaction Solutions

    ARIAD Pharmaceuticals, Inc. , a rare cancer-focused innovative biotechnology company, today announced a conference call and webcast to discuss the clinical data presented on brigatinib, the Company's investigational anaplastic lymphoma kinase inhibitor, at the International Association for the Study of Lung Cancer 17th World Conference on Lung Cancer . Timothy P. Clackson, Ph.D., president of research and development and chief scientific officer of ARIAD will host the call.

    Comment?

  6. First Circuit Affirms Tough Standard for Alleging Securities Fraud;...Read the original story w/Photo

    Thursday | JD Supra

    On November 28, 2016, the First Circuit upheld the dismissal of all but one of the class action securities fraud claims against Cambridge, MA drug company, ARIAD Pharmaceuticals, Inc., reaffirming the exacting pleading standards that enable defendants to put an early end to reflexive stock-drop lawsuits. In doing so, the First Circuit also adopted strict requirements for asserting claims that defendants misled investors in a common stock offering.

    Comment?

  7. First Circuit Strengthens "Traceability" Pleading Requirement for Section 11 ClaimsRead the original story w/Photo

    Wednesday Nov 30 | jdsupra.com

    ... registration statement, and not some other registration statement. In the First Circuit's In re: ARIAD Pharmaceuticals, Inc. Securities Litigation decision, No. 15-1491 (1st Cir. Nov. 28, 2016), the court held that plaintiffs cannot satisfy their ...

    Comment?

  8. Hedge Funds Are Souring On Chico's FAS, Inc.Read the original story w/Photo

    Tuesday Nov 29 | Insider Monkey

    ... the end of this article we will examine companies such as GW Pharmaceuticals PLC- ADR (NASDAQ: GWPH ), Ariad Pharmaceuticals, Inc. (NASDAQ: ARIA ), and BlackRock Credit All Inc Trust IV (NYSE: BTZ ) to gather more data points. At Insider Monkey, ...

    Comment?

  9. Securities fraud suit against drugmaker reinstatedRead the original story w/Photo

    Tuesday Nov 29 | Business Insurance

    A U.S. appellate court has reinstated securities fraud charges against a pharmaceuticals company because its officers allegedly provided an optimistic report about a trial drug shortly after the U.S. Food and Drug Administration had expressed reservations about it. In 2008, Cambridge, Massachusetts-based Ariad Pharmaceuticals Inc. began development of ponatinib, a drug designed to treat patients suffering from chronic myeloid leukemia, a cancer of the blood and bone marrow, according to Monday's ruling by the 1st U.S. Circuit Court of Appeals in Boston in In Re: Ariad Pharmaceuticals Inc. Securities Litigation .

    Comment?

  10. FDA fully approves ARIAD's Iclusig and a label update to include four-year follow-up dataRead the original story w/Photo

    Tuesday Nov 29 | Seeking Alpha

    The FDA grants full approval for ARIAD Pharmaceuticals' Iclusig for the treatment of adult patients with chronic phase, accelerated phase or blast phase chronic myeloid leukemia for whom no other TKI therapy is indicated and for the treatment of adult patients with T315I-positive CML or T315I-positive Ph+ acute lymphocytic leukemia. The agency also approved an update to Iclusig's label to include 48-month follow-up data from the Phase 2 PACE study.

    Comment?

  11. Leerink Swann Reiterates "Positive" Rating for Ariad Pharmaceuticals Inc.Read the original story

    Tuesday Nov 29 | AmericanBankingNews.com

    ... an "outperform" rating and set a $15.00 target price (up previously from $12.00) on shares of Ariad Pharmaceuticals in a research report on Friday, October 28th. Cowen and Company restated an "outperform" rating and issued a $16.00 price objective ...

    Comment?

  12. Ariad Announces FDA Full Approval And Label Update For Iclusig...Read the original story

    Monday Nov 28 | BioSpace

    ARIAD Pharmaceuticals, Inc. today announced that the U.S. Food and Drug Administration has granted IclusigA full approval for the treatment of adult patients with chronic phase, accelerated phase, or blast phase chronic myeloid leukemia or Philadelphia chromosome-positive acute lymphoblastic leukemia for whom no other tyrosine kinase inhibitor therapy is indicated; and for the treatment of adult patients with T315I-positive CML or T315I positive Ph+ ALL.

    Comment?

  13. In re: Ariad PharmaceuticalsRead the original story w/Photo

    Aug 1, 2016 | FindLaw

    In re: Ariad Pharmaceuticals, Inc. Securities Litigation Joseph Bradley; Pension Trust Fund for Operating Engineers; City of Fort Lauderdale Police & Fire Retirement System; Automotive Industries Pension Trust Fund; William A. Gaul, D.M.D., Plaintiffs, Appellants, Nabil Elmachtoub, individually and on behalf of all others similarly situated; James L. Burch, individually and on behalf of all others similarly situated; Greater Pennsylvania Carpenters' Pension Fund, individually and on behalf of all others similarly situated; Jimmy Wang, individually and on behalf of all others similarly situated, Plaintiffs, v.

    Comment?

  14. Hedge Funds Are Buzzing About GW Pharmaceuticals PLC- ADRRead the original story w/Photo

    Sunday Nov 27 | Insider Monkey

    ... than similarly priced stocks. That's why at the end of this article we will examine companies such as Ariad Pharmaceuticals, Inc. (NASDAQ: ARIA ), BlackRock Credit All Inc Trust IV (NYSE: BTZ ), and Grupo Financiero Galicia S.A. (ADR) (NASDAQ: GGAL ...

    Comment?

  15. Ariad Pharmaceuticals Inc. (ARIA) Receives Outperform Rating from Cowen and CompanyRead the original story w/Photo

    Saturday Nov 26 | AmericanBankingNews.com

    ... Blair reissued an "outperform" rating and set a $15.00 price target (up from $12.00) on shares of Ariad Pharmaceuticals in a research report on Friday, October 28th. Barclays PLC upped their price target on Ariad Pharmaceuticals from $8.00 to $9.00 ...

    Comment?

  16. Hedge Funds Are Betting On Ariad Pharmaceuticals, Inc.Read the original story w/Photo

    Saturday Nov 26 | Insider Monkey

    ... main reason why Insider Monkey takes notice of the hedge fund activity in these overlooked stocks. Is Ariad Pharmaceuticals, Inc. (NASDAQ: ARIA ) a healthy stock for your portfolio? Prominent investors are getting more optimistic. The number of ...

    Comment?

  17. Watch These Huge Put Purchases In Friday TradeRead the original story

    Friday Nov 25 | Benzinga

    ... ished intraday in Benzinga Professional . These trades were placed during Wednesday's regular session. Ariad Pharmaceuticals, Inc. (NASDAQ: ARIA ) Jan. $14 Puts Sweep at the Bid: Volume of 1,000 at $1.551 vs Open Interest 740

    Comment?

  18. Why PDL BioPharma Inc. Is Down 14.8% TodayRead the original story w/Photo

    Wednesday Nov 23 | Fox News

    ... to a slate of healthcare companies and has acquired royalty rights to drugs from both Depomed and Ariad Pharmaceuticals . In tapping investors with its notes offering, PDL BioPharma will pocket $145.8 million, after fees, of which $121.5 million ...

    Comment?

  19. Ariad Announces Data Presentations AtRead the original story

    Wednesday Nov 16 | BioSpace

    ARIAD Pharmaceuticals, Inc. , a rare cancer-focused innovative biotechnology company, today announced that clinical data on brigatinib, its investigational anaplastic lymphoma kinase inhibitor, will be presented at the International Association for the Study of Lung Cancer 17th World Conference on Lung Cancer being held in Vienna, December 4 to 7, 2016. "We are excited that updated data from the ALTA trial on brigatinib in patients with ALK-positive non-small cell lung cancer will be presented at WCLC this year.

    Comment?

  20. Ariad Pharmaceuticals' (ARIA) Buy Rating Reaffirmed at Leerink SwannRead the original story

    Thursday Nov 17 | AmericanBankingNews.com

    A number of other research analysts also recently commented on ARIA. Barclays PLC increased their price target on Ariad Pharmaceuticals from $8.00 to $9.00 and gave the company an "underweight" rating in a report on Friday, July 29th.

    Comment?